VIDEO: Cell therapy for corneal endothelial disease shows sustained improvements in BCVA
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Eris Jordan, OD, vice president of global clinical and medical affairs at Aurion Biotech, discusses the company’s novel cell therapy for corneal endothelial disease.
The company has opened an investigational new drug application for the treatment, which it plans to launch commercially in Japan next year. The first patients have also been dosed in the U.S. clinical trial investigating the cell therapy, Jordan said.
“I think what’s so unique about our program is the robust amount of clinical data that we have,” she said. “Aurion has conducted a metanalysis of the data and the patients that we’ve treated ... showing consistency in corneal clearance and sustained improvements in both central corneal thickness as well as best corrected visual acuity.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts